All Relations between Thalamus and Alzheimer Disease

Reference Sentence Publish Date Extraction Date Species
L Traykov, B Tavitian, A Jobert, F Boller, F Forette, C Crouzel, L Di Giamberardino, S Pappat. In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects. European journal of neurology vol 6 issue 3 2000 10210906 It is unclear whether the palliative effects of tetrahydroaminoacridine (THA) (tacrine, Cognex) on the clinical symptoms of patients affected by Alzheimer's disease (AD) are the result of its inhibitory activity on acetylcholinesterase or on other complex sites of action. 2000-06-26 2022-01-08 human
P Riekkinen, M Riekkine. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol 20 issue 4 1999 10088136 THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. 1999-06-03 2022-01-08 Not clear
P Riekkinen, M Riekkine. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol 20 issue 4 1999 10088136 We investigated the effects of a single administration of a cholinesterase inhibitor, tetrahydroaminoacridine (THA, 25 and 50 mg, orally), and an alpha 2-agonist, clonidine (0.5 and 2 micrograms/kg, orally), on neuropsychologic performance in two groups of patients with Alzheimer's disease (AD). 1999-06-03 2022-01-08 Not clear
D Lagadic-Gossmann, M Rissel, M A Le Bot, A Guillouz. Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell biology and toxicology vol 14 issue 5 1999 9808364 Administration of tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels. 1999-01-07 2022-01-08 Not clear
T M Itil, E Eralp, I Ahmed, A Kunitz, K Z Iti. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacology bulletin vol 34 issue 3 1998 9803773 Tacrine, also known as tetrahydroaminoacrine (THA), and donepezil are currently the only drugs approved in the United States for the treatment of Alzheimer's disease. 1998-12-09 2022-01-08 human
A V Gore, A C Liang, Y W Chie. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. Journal of pharmaceutical sciences vol 87 issue 4 1998 9548896 Tacrine (THA), a centrally acting acetylcholine-esterase inhibitor, is presently administered perorally for the treatment of Alzheimer's disease (AD). 1998-06-10 2022-01-08 Not clear
P Riekkinen, A P\\xc3\\xa4\\xc3\\xa4kk\\xc3\\xb6nen, J Karhu, J Partanen, H Soininen, M Laakso, P Riekkin. THA disrupts mismatch negativity in Alzheimer disease. Psychopharmacology vol 133 issue 2 1997 9342788 THA disrupts mismatch negativity in Alzheimer disease. 1997-11-20 2022-01-08 human
P Riekkinen, A P\\xc3\\xa4\\xc3\\xa4kk\\xc3\\xb6nen, J Karhu, J Partanen, H Soininen, M Laakso, P Riekkin. THA disrupts mismatch negativity in Alzheimer disease. Psychopharmacology vol 133 issue 2 1997 9342788 The present study investigates the effects of 25 or 50 mg tetrahydroaminoacridine (THA), a cholinesterase inhibitor, on auditory mismatch negativity (MMN) event-related response in 19 patients with Alzheimer disease (AD). 1997-11-20 2022-01-08 human
P Riekkinen, H Soininen, J Partanen, A P\\xc3\\xa4\\xc3\\xa4kk\\xc3\\xb6nen, S Helisalmi, P Riekkine. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology vol 129 issue 3 1997 9084068 The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. 1997-11-19 2022-01-07 Not clear
C Ibebunjo, F Donati, G S Fox, D Eshelby, J I Tchervenko. The effects of chronic tacrine therapy on d-tubocurarine blockade in the soleus and tibialis muscles of the rat. Anesthesia and analgesia vol 85 issue 2 1997 9249126 Tacrine (THA) is an anticholinesterase drug used to manage Alzheimer's dementia, but it is not clear how its chronic use might affect response to nondepolarizing muscle relaxants. 1997-09-03 2022-01-08 rat
C Ibebunjo, F Donati, G S Fox, D Eshelby, J I Tchervenko. The effects of chronic tacrine therapy on d-tubocurarine blockade in the soleus and tibialis muscles of the rat. Anesthesia and analgesia vol 85 issue 2 1997 9249126 The same may apply to Alzheimer's patients taking THA chronically. 1997-09-03 2022-01-08 rat
P Riekkinen, M Riekkinen, H Soininen, J Kuikka, M Laakso, P Riekkine. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport vol 8 issue 8 1997 9223063 Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. 1997-08-29 2022-01-08 Not clear
P Riekkinen, M Riekkinen, H Soininen, J Kuikka, M Laakso, P Riekkine. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport vol 8 issue 8 1997 9223063 We evaluated the effect of a single dose of a cholinesterase inhibitor, tetrahydroaminoacridine (THA; 25 and 50 mg, orally), on attention in patients with Alzheimer's disease (AD). 1997-08-29 2022-01-08 Not clear
C D Bonan, A M Battastini, M R Schetinger, C M Moreira, S S Frassetto, R D Dias, J J Sarki. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA) on ATP diphosphohydrolase (EC 3.6.1.5) and 5'-nucleotidase (EC 3.1.3.5) from rat brain synaptosomes. General pharmacology vol 28 issue 5 1997 9184816 THA, proposed as a drug for the treatment of Alzheimer's disease, can alter in vitro ATP degradation in synaptosomes from the central nervous system. 1997-08-15 2022-01-08 rat
Y Mimori, S Nakamura, M Yukaw. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behavioural brain research vol 83 issue 1-2 1997 9062656 AChE inhibitors, including physostigmine, E-2020, amiridin, tetrahydroaminoacridine (THA) and Nicergoline had a poor effect on AChE present in the senile plaque-rich fraction isolated from Alzheimer brain than that either in the soluble fraction of Alzheimer brain or in the control brain. 1997-07-09 2022-01-07 Not clear
G G Benoit, C F Naud, M A Simard, A L Astie. Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. Biochemical pharmacology vol 53 issue 3 1997 9065747 Tacrine (THA) is the only drug currently approved for the treatment of Alzheimer's disease. 1997-04-07 2022-01-07 Not clear
W P McNally, W F Pool, M W Sinz, P Dehart, D F Ortwine, C C Huang, T Chang, T F Wool. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. Drug metabolism and disposition: the biological fate of chemicals vol 24 issue 6 1997 8781777 Tacrine [1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate (THA), Cognex] is a potent acetylcholinesterase inhibitor recently approved for treatment of mild-to-moderate Alzheimer's disease. 1997-03-18 2022-01-07 rat
W P McNally, W F Pool, M W Sinz, P Dehart, D F Ortwine, C C Huang, T Chang, T F Wool. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. Drug metabolism and disposition: the biological fate of chemicals vol 24 issue 6 1997 8781777 The relevance of THA accumulation in brain tissue to delays observed in THA clinical management of Alzheimer's disease remains to be established. 1997-03-18 2022-01-07 rat
N Katsube, K Sunaga, D M Chuang, R Ishitan. ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neuroscience letters vol 214 issue 2-3 1997 8878106 The common actions of ONO-1603 and THA suggest that these properties could be related to their putative antidementia activities and that this model system may be used to screen for drugs effective in the treatment for Alzheimer's disease. 1997-01-31 2022-01-07 Not clear
A A al-Jafari, M A Kama. Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (Camelus dromedarius) retina acetylcholinesterase. Biochemistry and molecular biology international vol 39 issue 5 1997 8866008 Therefore, THA's effect on turnover number must be considered at the time of therapy to the Alzheimer's disease patients. 1997-01-27 2022-01-07 Not clear
Y P Pang, P Quiram, T Jelacic, F Hong, S Brimijoi. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. The Journal of biological chemistry vol 271 issue 39 1996 8798583 Applying this strategy to 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug for Alzheimer's disease, we obtained alkylene linked bis-THA analogs. 1996-11-18 2022-01-07 Not clear
P Zatta, P Zambenedetti, M B Marturano, M Palumbo, M Nicolin. Effects of tacrine upon murine neuroblastoma cells. Journal of neural transmission. General section vol 102 issue 2 1996 8748676 Tacrine [9-amino-1,2,3,4-tetrahydroacridine] (THA), a potent acetylcholinesterasic inhibitor, is utilized in the pharmacological treatment of Alzheimer's disease (Birne and Arie, 1994). 1996-10-24 2022-01-07 Not clear
A Ahlin, T Junth\\xc3\\xa9, M Hassan, H Nyb\\xc3\\xa4c. One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type. International psychogeriatrics vol 7 issue 1 1995 7579023 One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type. 1995-12-01 2022-01-07 Not clear
A Ahlin, T Junth\\xc3\\xa9, M Hassan, H Nyb\\xc3\\xa4c. One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type. International psychogeriatrics vol 7 issue 1 1995 7579023 Fourteen patients suffering from dementia of the Alzheimer type were treated with tacrine (tetrahydroaminoacridine, THA) for 1 year in an open trial. 1995-12-01 2022-01-07 Not clear
J G Shaddock, R J Feuers, M W Chou, D H Swenson, D A Cascian. Genotoxicity of tacrine in primary hepatocytes isolated from B6C3F1 mice and aged ad libitum and calorie restricted Fischer 344 rats. Mutation research vol 344 issue 1-2 1995 7565897 Tacrine (1,2,3,4-tetrahydro-9-aminoacridine; THA), a reversible centrally acting anticholinesterase, has been shown to be potentially useful for treatment of patients with Alzheimer's disease. 1995-10-25 2022-01-07 rat
P Riekkinen, H Soininen, E L Helkala, K Partanen, M Laakso, M Vanhanen, P Riekkine. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport vol 6 issue 9 1995 7669991 Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. 1995-10-19 2022-01-07 Not clear
P Dell'Antone, M Bragadin, P Zatt. Anticholinesterasic drugs: tacrine but not physostigmine, accumulates in acidic compartments of the cells. Biochimica et biophysica acta vol 1270 issue 2-3 1995 7727536 Tacrine (THA) and physostigmine (PHS) have been used in Alzheimer's disease therapy for their anticholinesterasic activity. 1995-05-31 2022-01-07 Not clear
P Dell'Antone, M Bragadin, P Zatt. Anticholinesterasic drugs: tacrine but not physostigmine, accumulates in acidic compartments of the cells. Biochimica et biophysica acta vol 1270 issue 2-3 1995 7727536 The accumulation of THA in acidic organelles of the cell may be relevant for the pharmacological action of THA in Alzheimer's treatment. 1995-05-31 2022-01-07 Not clear
A Ahlin, M Hassan, T Junth\\xc3\\xa9, H Nyb\\xc3\\xa4c. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration. International clinical psychopharmacology vol 9 issue 4 1995 7868848 In a previous pharmacokinetic study in Alzheimer patients great inter-individual variation and low oral bioavailability of the cholinesterase inhibitor tacrine (tetrahydroaminoacridine, THA) were found. 1995-03-29 2022-01-07 Not clear
B J Sahakian, A M Owen, N J Morant, S A Eagger, S Boddington, L Crayton, H A Crockford, M Crooks, K Hill, R Lev. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology vol 110 issue 4 1995 7870908 Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. 1995-03-29 2022-01-07 Not clear
B J Sahakian, A M Owen, N J Morant, S A Eagger, S Boddington, L Crayton, H A Crockford, M Crooks, K Hill, R Lev. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology vol 110 issue 4 1995 7870908 Results of a placebo controlled cross-over trial (N = 89) of the anticholinesterase drug THA as a treatment for dementia of the Alzheimer's type (DAT) are reported, with reference to previous trials of the drug and the cholinergic hypothesis of aging and dementia. 1995-03-29 2022-01-07 Not clear
J Chelliah, J D Smith, M W Faris. Inhibition of cholinesterase activity by tetrahydroaminoacridine and the hemisuccinate esters of tocopherol and cholesterol. Biochimica et biophysica acta vol 1206 issue 1 1994 8186246 Such potent and synergistic inhibition of AChE suggest that TS or CS, alone and in combination with THA, may prove beneficial in the treatment of organophosphate poisoning and Alzheimer's disease. 1994-06-21 2022-01-07 Not clear
H Nyb\\xc3\\xa4ck, M Hassan, T Junth\\xc3\\xa9, A Ahli. Clinical experiences and biochemical findings with tacrine (THA). Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 7510447 A clinical comparison of tacrine (THA) and placebo was performed in 15 Alzheimer patients using a double blind crossover technique over 4 plus 4 weeks with one drug-free week in between. 1994-04-14 2022-01-07 human
A Ade. The next generation of cholinesterase inhibitors. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128831 Clinical trials with tacrine (THA) have resulted in elevations of liver enzymes in Alzheimer patients that showed improvement. 1994-04-14 2022-01-07 rat
A Ade. The next generation of cholinesterase inhibitors. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128831 It is possible that some of these analogues with more potent cholinergic effect than THA might be the next generation of cholinesterase inhibitors which can be useful in the treatment of Alzheimer's disease. 1994-04-14 2022-01-07 rat
B J Sahakian, J T Coul. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128835 Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. 1994-04-14 2022-01-07 Not clear
B J Sahakian, J T Coul. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128835 A placebo-controlled cross-over trial (n = 89) investigated the use of a chronic dose of the cholinesterase inhibitor THA, as a treatment for dementia of the Alzheimer type (DAT). 1994-04-14 2022-01-07 Not clear
K Amberla, A Nordberg, M Viitanen, B Winbla. Long-term treatment with tacrine (THA) in Alzheimer's disease--evaluation of neuropsychological data. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128841 Long-term treatment with tacrine (THA) in Alzheimer's disease--evaluation of neuropsychological data. 1994-04-14 2022-01-07 Not clear
M Shigeta, A Persson, M Viitanen, B Winblad, A Nordber. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128842 EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease. 1994-04-14 2022-01-07 Not clear
M Shigeta, A Persson, M Viitanen, B Winblad, A Nordber. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128842 Three patients with Alzheimer's disease of mild type received long-term treatment with THA at doses between 40 mg to 160 mg daily. 1994-04-14 2022-01-07 Not clear
A Nordber. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta neurologica Scandinavica. Supplementum vol 149 issue 1994 8128843 Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. 1994-04-14 2022-01-07 Not clear
G K Wilcock, D J Surmon, M Scott, M Boyle, K Mulligan, K A Neubauer, D O'Neill, V H Roysto. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age and ageing vol 22 issue 5 1993 8237620 An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. 1993-12-17 2022-01-07 human
G K Wilcock, D J Surmon, M Scott, M Boyle, K Mulligan, K A Neubauer, D O'Neill, V H Roysto. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age and ageing vol 22 issue 5 1993 8237620 Seventy-nine patients with probable Alzheimer's disease were enrolled into a double-blind, placebo-controlled cross-over study to assess the therapeutic effect and safety of THA (tetrahydroaminoacridine; tacrine) without concomitant lecithin administration. 1993-12-17 2022-01-07 human
C J Viau, R D Curren, K Wallac. Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. Drug and chemical toxicology vol 16 issue 3 1993 8404544 Clinical trials with tacrine (THA) and its principal (1-OH) metabolite (velnacrine) for the treatment of Alzheimer's disease have been hampered by adverse hepatic events that were undetected in preclinical studies. 1993-11-04 2022-01-07 Not clear
K Alhainen, E L Helkala, K Reinikainen, P Riekkine. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. Journal of neural transmission. Parkinson's disease and dementia section vol 5 issue 3 1993 7690228 The effect of tetrahydroaminoacridine (THA) on the cerebrospinal fluid (CSF) monoamine metabolites was studied in 22 patients with Alzheimer's disease in an open treatment trial. 1993-10-12 2022-01-07 Not clear
K Alhainen, E L Helkala, P Riekkine. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients. Dementia (Basel, Switzerland) vol 4 issue 1 1993 8358507 Fourteen patients with probable Alzheimer's disease (AD) participated in an open tetrahydroaminoacridine (THA) treatment trial. 1993-09-30 2022-01-07 Not clear
D Petit, J Montplaisir, D Lorrain, S Gauthie. THA does not affect sleep or EEG spectral power in Alzheimer's disease. Biological psychiatry vol 33 issue 10 1993 8353172 THA does not affect sleep or EEG spectral power in Alzheimer's disease. 1993-09-22 2022-01-07 Not clear
K M Perryman, L J Fitte. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life sciences vol 53 issue 6 1993 8341134 Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. 1993-08-31 2022-01-07 human
K M Perryman, L J Fitte. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life sciences vol 53 issue 6 1993 8341134 During a double blind, inpatient-outpatient study of THA (tacrine) and lecithin in Alzheimer's disease, data on a laboratory-based delayed-matching-to-sample (DMS) test was collected on six of 10 subjects. 1993-08-31 2022-01-07 human
P E Potter, S Nitt. Alterations in modulation of acetylcholine release following lesion of hippocampal cholinergic neurons with the neurotoxin AF64A. Neuropharmacology vol 32 issue 6 1993 8336816 However, in cerebral cortical slices from patients with Alzheimer's disease, ACh release is enhanced by THA, an effect mediated via nicotinic receptors. 1993-08-25 2022-01-07 rat
B Tavitian, S Pappata, S Bonnot-Lours, C Prenant, A Jobert, C Crouzel, L Di Giamberardin. Positron emission tomography study of [11C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain. European journal of pharmacology vol 236 issue 2 1993 8319751 THA (1,2,3,4-tetrahydro-9-amino-acridine, tacrine), a potential therapeutic agent for patients suffering from Alzheimer's disease, has multiple pharmacological sites of action in the brain. 1993-08-05 2022-01-07 Not clear
W B Xiao, A Nordberg, X Zhan. Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats. The Journal of pharmacology and experimental therapeutics vol 265 issue 2 1993 8496822 1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer's disease. 1993-06-22 2022-01-07 rat
G Fredj, F Dietlin, G Barbier, C Jasmin, L Bonhomme, S Esctein, J L Misset, P Meyer, D Kalifa, T Beugr. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS]. Therapie vol 47 issue 3 1993 1295125 Previously used in Alzheimer disease Tacrine (THA): tetrahydroaminoacridine has shown a rise of hepatic transaminase enzyme activity (TEA) in 18% of patients for Summers and 19% for Ames. 1993-04-12 2022-01-07 Not clear
G Fredj, F Dietlin, G Barbier, C Jasmin, L Bonhomme, S Esctein, J L Misset, P Meyer, D Kalifa, T Beugr. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS]. Therapie vol 47 issue 3 1993 1295125 Although studies using THA from USA or Canada have noticed a rise of TEA in 30% of the patients, after a treatment course with French THA we also have noted a rise of TEA in 12% of the Alzheimer patients. 1993-04-12 2022-01-07 Not clear
G Fredj, F Dietlin, G Barbier, C Jasmin, L Bonhomme, S Esctein, J L Misset, P Meyer, D Kalifa, T Beugr. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS]. Therapie vol 47 issue 3 1993 1295125 52 patients with HIV infection (26 in the IVC1 group and 26 in IVC2 group) have been treated with the same THA as the one used for Alzheimer french group. 1993-04-12 2022-01-07 Not clear
G Fredj, F Dietlin, G Barbier, C Jasmin, L Bonhomme, S Esctein, J L Misset, P Meyer, D Kalifa, T Beugr. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS]. Therapie vol 47 issue 3 1993 1295125 These results observed in HIV advanced patients with this THA are discordant with the one observed in Alzheimer's study. 1993-04-12 2022-01-07 Not clear
S Liu, D M Sylveste. The inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on platelet function. Thrombosis research vol 67 issue 5 1992 1448787 Tetrahydroacridine (THA), or Cognex, is currently awaiting FDA approval for the treatment of Alzheimer's disease. 1992-12-30 2022-01-07 Not clear
S Liu, D M Sylveste. The inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on platelet function. Thrombosis research vol 67 issue 5 1992 1448787 In addition to reports indicating that THA improves the symptoms of patients with Alzheimer's disease, we have found that THA possesses potent antiplatelet activity. 1992-12-30 2022-01-07 Not clear
S S Jossan, A Adem, B Winblad, L Orelan. Characterisation of dopamine and serotonin uptake inhibitory effects of tetrahydroaminoacridine in rat brain. Pharmacology & toxicology vol 71 issue 3 Pt 1 1992 1438045 The re-uptake blocking effect of THA on dopaminergic and serotonergic neurones, following THA treatment, might lead to increased levels of these monoamines in brains of Alzheimer patients and contribute in the therapeutic effects of the drug. 1992-12-04 2022-01-07 Not clear
I Nordgren, B Karl\\xc3\\xa9n, M Kimlan. Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain. Pharmacology & toxicology vol 71 issue 3 Pt 1 1992 1438050 Tetrahydroaminoacridine (THA) and metrifonate are cholinesterase inhibitors used in the treatment of Alzheimer's disease. 1992-12-04 2022-01-07 Not clear
A Ahlin, A Adem, T Junth\\xc3\\xa9, G Ohman, H Nyb\\xc3\\xa4c. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients. International clinical psychopharmacology vol 7 issue 1 1992 1624754 The pharmacokinetics of tetrahydroaminoacridine (THA) was studied in patients suffering from Alzheimer's dementia. 1992-08-07 2022-01-07 human
D A Butterfield, A Rangachar. Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease. Biochemical and biophysical research communications vol 185 issue 2 1992 1319141 The interaction of pharmacological agents potentially useful in Alzheimer's disease, 9-amino-1,2,3,4-tetrahydroacridine (THA or tacrine) and its major metabolite velnacrine (or HP-029), along with related compounds with cytoskeletal proteins in human erythrocyte membrane was investigated using electron paramagnetic resonance spin labeling techniques. 1992-07-21 2022-01-07 Not clear
M B Cohen, L J Fitten, R R Lake, K M Perryman, L S Graham, R Sevri. SPECT brain imaging in Alzheimer's disease during treatment with oral tetrahydroaminoacridine and lecithin. Clinical nuclear medicine vol 17 issue 4 1992 1572123 Quantitative SPECT brain imaging was performed in five normal subjects and in six ambulatory patients with Alzheimer's disease before the initiation of treatment with tetrahydroaminoacridine (THA) and lecithin. 1992-06-04 2022-01-07 human
M B Cohen, L J Fitten, R R Lake, K M Perryman, L S Graham, R Sevri. SPECT brain imaging in Alzheimer's disease during treatment with oral tetrahydroaminoacridine and lecithin. Clinical nuclear medicine vol 17 issue 4 1992 1572123 No dramatic clinical or behavioral change in cerebral perfusion was observed from initial treatment of Alzheimer's disease with THA and lecithin. 1992-06-04 2022-01-07 human
L J Fitten, S Ganzel. Spouses' assessments of Alzheimer patients' response to THA and lecithin. The American journal of psychiatry vol 149 issue 4 1992 1554054 Spouses' assessments of Alzheimer patients' response to THA and lecithin. 1992-04-29 2022-01-07 Not clear
H A Berman, K Leonar. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Molecular pharmacology vol 41 issue 2 1992 1538717 This paper examines inhibition of acetylcholinesterase (AchE) and butyrylcholinesterase (BuchE) by tetrahydroaminoacridine (THA), an acridine analog under consideration for palliative treatment of Alzheimer's dementia. 1992-03-27 2022-01-09 Not clear
M Dierssen, F M\\xc3\\xa0rmol, N M Vivas, M V Clos, S Gasc\\xc3\\xb3n, A Badi. Acute effects of tetrahydroaminoacridine on beta-adrenoceptor-linked cyclic AMP accumulation in brain of young and middle-aged rats. Neuroscience letters vol 132 issue 1 1992 1724070 The effects of acute treatment with 1,2,3,4-tetrahydro-9-aminoacridine (THA), a 4-aminopyridine derivative clinically effective in Alzheimer's disease, on beta-adrenoceptor-linked cyclic AMP accumulation have been investigated in cortical and hippocampal structures of young and middle-aged rats. 1992-03-26 2022-01-07 rat
L S Schneider, S A Lyness, S Pawluczyk, R P Gleason, R B Sloan. Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report. Psychopharmacology bulletin vol 27 issue 3 1992 1775604 Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? 1992-03-02 2022-01-07 Not clear
R Krishnara. Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down-regulation of natural cell-mediated cytotoxicity in vitro. Immunopharmacology vol 22 issue 2 1992 1761401 THA (Tacrine), a drug used in the experimental therapy of dementia of Alzheimer's disease type, and whose biochemical site of action is believed to be the neural cholinesterase, is shown, for the first time, to be an immunosuppressant in vitro on normal human peripheral blood lymphocytes in microgram quantities. 1992-02-07 2022-01-07 Not clear
W A van Gool, J Waardenburg, F E Meyjes, H C Weinstein, A de Wild. The effect of tetrahydroaminoacridine (THA) on P300 in Alzheimer's disease. Biological psychiatry vol 30 issue 9 1992 1747439 The effect of tetrahydroaminoacridine (THA) on P300 in Alzheimer's disease. 1992-01-22 2022-01-07 Not clear
J P Kesslak, A Korotzer, A Song, K Kamali, C W Cotma. Effects of tetrahydroaminoacridine (THA) on functional recovery after sequential lesion of the entorhinal cortex. Brain research vol 557 issue 1-2 1992 1747769 The failure of THA to significantly improve functional recovery in rats with lesions of the entorhinal cortex indicates that the compound may have limited applicability in treating human neurodegenerative disorders such as Alzheimer's disease. 1992-01-22 2022-01-07 rat
K Alhainen, J Sirvi\\xc3\\xb6, E L Helkala, K Reinikainen, P Riekkine. Somatostatin and cognitive functions in Alzheimer's disease--the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. Neuroscience letters vol 130 issue 1 1992 1684233 We studied the effect of tetrahydroaminoacridine (THA) on cerebrospinal fluid somatostatin-like immunoreactivity (CSF-SLI) in probable Alzheimer disease (AD) patients (n = 20) who took part in an open THA treatment trial. 1992-01-21 2022-01-07 Not clear
K M Perryman, L J Fitte. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. Journal of geriatric psychiatry and neurology vol 4 issue 3 1991 1953964 Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. 1991-12-27 2022-01-07 Not clear
K M Perryman, L J Fitte. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. Journal of geriatric psychiatry and neurology vol 4 issue 3 1991 1953964 Quantitative electroencephalography (EEG) was performed on eight of ten Alzheimer patients in a double-blind, inpatient-outpatient tetrahydroaminoacridine (THA) and lecithin trial. 1991-12-27 2022-01-07 Not clear
F Elinder, P Arhe. Mechanisms of the tetrahydroaminoacridine effect on action potential and ion currents in myelinated axons. European journal of pharmacology vol 208 issue 1 1991 1936128 The findings suggest an explanation to some aspects of the clinical effects of THA on Alzheimer patients. 1991-12-17 2022-01-07 xenopus_laevis
K Alhainen, J Partanen, K Reinikainen, V Laulumaa, H Soininen, M Airaksinen, P Riekkine. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neuroscience letters vol 127 issue 1 1991 1881606 We report the results of our study suggesting that a single dose pharmaco-EEG may predict treatment response to tetrahydroaminoacridine (THA) in Alzheimer's disease (AD). 1991-09-30 2022-01-07 Not clear
N Hershkowitz, M A Rogawsk. Tetrahydroaminoacridine block of N-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons. Molecular pharmacology vol 39 issue 5 1991 1709720 The action of tetrahydroaminoacridine (THA), a centrally active cholinesterase inhibitor that may provide symptomatic benefit in Alzheimer's disease, was studied on responses to the excitatory amino acid N-methyl-D-aspartate (NMDA) in cultured hippocampal neurons, using whole-cell voltage-clamp and single-channel recording techniques. 1991-06-21 2022-01-07 Not clear
H C Weinstein, S Teunisse, W A van Goo. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers. Journal of neurology vol 238 issue 1 1991 2030370 In 12 ambulant patients with a clinical diagnosis of probable Alzheimer's disease, a 12-week, double-blind, placebo-controlled study with 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin is reported. 1991-06-17 2022-01-07 Not clear
E E Mena, M C Desa. High-affinity [3H]THA (tetrahydroaminoacridine) binding sites in rat brain. Pharmaceutical research vol 8 issue 2 1991 2023867 Tetrahydroaminoacridine (THA), an acetylcholinesterase inhibitor that is reported to have significant effects on cognition and memory in Alzheimer's disease patients, binds to rat brain membranes in a saturable and reversible manner. 1991-05-31 2022-01-07 Not clear
A K Mohammed, G Wahlstr\\xc3\\xb6m, T Archer, A Nordber. Learning deficits in aged rats pretreated chronically with barbital and tested late in abstinence: alleviation by tetrahydroaminoacridine. Journal of neural transmission. Parkinson's disease and dementia section vol 2 issue 4 1991 2078308 Physostigmine and tetrahydroaminoacridine (THA) have been reported to improve cognitive function in patients with Alzheimer's disease. 1991-05-01 2022-01-07 rat
R S Hsu, G M Shutske, E M Dileo, S M Chesson, A R Linville, R C Alle. Identification of the urinary metabolites of tacrine in the rat. Drug metabolism and disposition: the biological fate of chemicals vol 18 issue 5 1991 1981736 Tacrine (THA) is a potent cholinesterase inhibitor being studied for the treatment of Alzheimer's disease. 1991-04-25 2022-01-07 rat
D W Molloy, G H Guyatt, D B Wilson, R Duke, L Rees, J Singe. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol 144 issue 1 1991 1984813 To determine the efficacy of tetrahydroaminoacridine (THA) in Alzheimer's disease. 1991-02-04 2022-01-07 Not clear
A Adem, A K Mohammed, B Winbla. Multiple effects of tetrahydroaminoacridine on the cholinergic system: biochemical and behavioural aspects. Journal of neural transmission. Parkinson's disease and dementia section vol 2 issue 2 1990 2222779 9-Amino-1,2,3,4-tetrahydroaminoacridine (THA) in combination with lecithin has been reported to improve the memory of Alzheimer's disease patients. 1990-12-13 2022-01-07 rat
A Adem, A K Mohammed, B Winbla. Multiple effects of tetrahydroaminoacridine on the cholinergic system: biochemical and behavioural aspects. Journal of neural transmission. Parkinson's disease and dementia section vol 2 issue 2 1990 2222779 Moreover, THA showed similar affinity for temporal cortices muscarinic receptors from Alzheimer and non-Alzheimer (control) brains. 1990-12-13 2022-01-07 rat
C Peterso. Tetrahydroaminoacridine increases acetylcholine synthesis and glucose oxidation by mouse brain slices in vitro. Neuroscience letters vol 115 issue 2-3 1990 2234505 1,2,3,4-Tetrahydro-5-aminoacridine (THA; tacrine) reportedly improves cognitive deficits in certain individuals with Alzheimer's disease. 1990-12-12 2022-01-07 Not clear
C Peterso. Tetrahydroaminoacridine increases acetylcholine synthesis and glucose oxidation by mouse brain slices in vitro. Neuroscience letters vol 115 issue 2-3 1990 2234505 Thus the efficacy of THA treatment on Alzheimer patients may be partially related to increased ACh synthesis and oxidative metabolism. 1990-12-12 2022-01-07 Not clear
L J Tha. THA, a putative drug in the treatment of Alzheimer's disease? Acta neurologica Scandinavica. Supplementum vol 129 issue 1990 2220321 THA, a putative drug in the treatment of Alzheimer's disease? 1990-11-06 2022-01-07 Not clear
P Cumming, P B Reiner, S R Vincen. Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA). Biochemical pharmacology vol 40 issue 6 1990 2403387 9-Amino-1,2,3,4-tetrahydroacridine (THA), an inhibitor of acetylcholinesterase, has been proposed as a treatment for Alzheimer's disease on the basis of its ability to increase cerebral levels of acetylcholine. 1990-10-22 2022-01-07 Not clear
D A Butterfield, D A Palmier. Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes. Free radical research communications vol 9 issue 3-6 1990 2167274 Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes. 1990-09-25 2022-01-07 Not clear
D A Butterfield, D A Palmier. Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes. Free radical research communications vol 9 issue 3-6 1990 2167274 These results are discussed in relation to possible interaction sites of THA in erythrocyte ghosts and to potential mechanisms by which THA reportedly increases mental function of victims of Alzheimer's disease. 1990-09-25 2022-01-07 Not clear
D A Palmieri, D A Butterfiel. Structure-activity investigation of the alteration of the physical state of the skeletal network of proteins in human erythrocyte membranes induced by 9-amino-1,2,3,4-tetrahydroacridine. Biochimica et biophysica acta vol 1024 issue 2 1990 2354181 The oral administration of 9-amino-1,2,3,4-tetrahydroacridine (THA) is purported to increase the mental function of Alzheimer's disease patients (Summers et al. 1990-07-26 2022-01-07 Not clear
H Brodat. The use of THA for Alzheimer's disease. The Medical journal of Australia vol 152 issue 11 1990 2348794 The use of THA for Alzheimer's disease. 1990-07-11 2022-01-07 Not clear
D J Ames, P S Bhathal, B M Davies, J R Fraser, P R Gibson, S Robert. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Australian and New Zealand journal of medicine vol 20 issue 2 1990 2344330 Of 14 patients taking tetrahydroaminoacridine (THA) for the trial treatment of Alzheimer's disease, five developed mildly abnormal liver function tests. 1990-06-26 2022-01-07 human
D J Ames, P S Bhathal, B M Davies, J R Fraser, P R Gibson, S Robert. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Australian and New Zealand journal of medicine vol 20 issue 2 1990 2344330 Patients receiving THA for treatment of Alzheimer's disease need regular monitoring of liver function. 1990-06-26 2022-01-07 human
S Gauthier, R Bouchard, A Lamontagne, P Bailey, H Bergman, J Ratner, Y Tesfaye, M Saint-Martin, Y Bacher, L Carrie. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. The New England journal of medicine vol 322 issue 18 1990 2183056 We studied the efficacy and safety of oral tetrahydroaminoacridine (THA) combined with lecithin in 52 patients with Alzheimer's disease. 1990-05-24 2022-01-07 Not clear
G Chatellier, L Lacomble. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\\xc3\\xa7ais d'Etude de la Tetrahydroaminoacridine. BMJ (Clinical research ed.) vol 300 issue 6723 1990 2107926 Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. 1990-05-10 2022-01-07 Not clear
G Chatellier, L Lacomble. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\\xc3\\xa7ais d'Etude de la Tetrahydroaminoacridine. BMJ (Clinical research ed.) vol 300 issue 6723 1990 2107926 To see whether combined treatment with oral tacrine (tetrahydroaminoacridine; THA) and lecithin improves the symptoms of patients with Alzheimer's disease. 1990-05-10 2022-01-07 Not clear
A Adem, S S Jossan, L Orelan. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neuroscience letters vol 107 issue 1-3 1990 2616041 Thus it is possible that inhibition of MAO may be involved in the therapeutic action of THA in Alzheimer's disease. 1990-03-14 2022-01-07 Not clear
W K Summers, K H Tachiki, A Klin. Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies. European neurology vol 29 Suppl 3 issue 1990 2693104 The initial report of the effectiveness of tacrine or tetrahydroaminoacridine (THA) in the treatment of some patients with Alzheimer's disease has been confirmed by further study of additional subjects and by preliminary reports from other investigators. 1990-03-05 2022-01-07 human
L J Fitten, K M Perryman, P L Gross, H Fine, J Cummins, C Marshal. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. The American journal of psychiatry vol 147 issue 2 1990 2405720 Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. 1990-03-02 2022-01-07 Not clear
L J Fitten, K M Perryman, P L Gross, H Fine, J Cummins, C Marshal. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. The American journal of psychiatry vol 147 issue 2 1990 2405720 Ten Alzheimer's disease patients underwent a trial of oral tetrahydroaminoacridine (THA) and lecithin. 1990-03-02 2022-01-07 Not clear
J A Nielsen, E E Mena, I H Williams, M R Nocerini, D Listo. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. European journal of pharmacology vol 173 issue 1 1990 2606156 9-Amino-1,2,3,4-tetrahydroacridine (THA) has been reported to cause improvement in patients with senile dementia of the Alzheimer's type. 1990-02-22 2022-01-07 rat
J A Nielsen, E E Mena, I H Williams, M R Nocerini, D Listo. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. European journal of pharmacology vol 173 issue 1 1990 2606156 We conclude that brain AChE inhibition by THA is sufficient to explain its purported therapeutic activity in Alzheimer's disease and that its favorable brain/plasma distribution in vivo may account for its central cholinergic action without inducing the severe peripheral cholinergic effects typically seen with other AChE inhibitors. 1990-02-22 2022-01-07 rat
A Nordberg, L Nilsson-H\\xc3\\xa5kansson, A Adem, Z Lai, B Winbla. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains. Progress in clinical and biological research vol 317 issue 1990 2557636 Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains. 1990-01-31 2022-01-07 rat
A Nordberg, L Nilsson-H\\xc3\\xa5kansson, A Adem, Z Lai, B Winbla. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains. Progress in clinical and biological research vol 317 issue 1990 2557636 1,2,3,4-tetrahydro-9-aminoacridine (THA) is a cholinesterase inhibitor presently under investigation in clinical trials for treatment of Alzheimer's disease, senile dementia of Alzheimer type (AD/SDAT). 1990-01-31 2022-01-07 rat
K A Sherman, E Messamor. Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us? Progress in clinical and biological research vol 317 issue 1990 2602408 Despite a strong rationale for the use of cholinesterase (ChE) inhibitors and related drugs to augment cholinergic function as palliative treatment for Alzheimer dementia, this approach met with limited and variable success until the striking results recently reported with tacrine (THA). 1990-01-31 2022-01-07 rat
V Kumar, R E Becke. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease. International journal of clinical pharmacology, therapy, and toxicology vol 27 issue 10 1990 2684868 Tetrahydroaminoacridine (THA) was administered to a small number of patients with Alzheimer's disease. 1990-01-04 2022-01-07 Not clear
F Boller, F Forett. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol 43 issue 7 1989 2684292 Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. 1989-12-28 2022-01-07 Not clear
G Fredj, F Dietlin, D Fredj, L Schwarzenberg, C Jasmin, P Meyer, J L Misse. Tetrahydroaminoacridine in HIV infections. The THA Study Group. International journal of clinical pharmacology, therapy, and toxicology vol 27 issue 8 1989 2793276 On the basis of a similarity between certain neurological symptoms of AIDS and Alzheimer's disease, the authors studied the effects of tetrahydroaminoacridine (THA) in 9 patients with HIV infection. 1989-11-06 2022-01-07 Not clear
P L Moriearty, W Kenny, V Kuma. Estimation of plasma tacrine concentrations using an in vitro cholinesterase inhibition assay. Alzheimer disease and associated disorders vol 3 issue 3 1989 2789791 THA (9-amino, 1,2,3,4-tetrahydroacridine; tacrine) is currently under study as a cholinesterase (ChE) inhibitor in Alzheimer disease. 1989-11-02 2022-01-07 Not clear
A Sattin, B B Muhoberac, M H Aprison, C L Schau. Tetrahydroaminoacridine (THA) as a pharmacological probe in Alzheimer's disease (AD) and other neurodegenerative disorders. Medical hypotheses vol 29 issue 3 1989 2779475 Tetrahydroaminoacridine (THA) as a pharmacological probe in Alzheimer's disease (AD) and other neurodegenerative disorders. 1989-10-13 2022-01-07 Not clear
G M Shutske, F A Pierrat, K J Kapples, M L Cornfeldt, M R Szewczak, F P Huger, G M Bores, V Haroutunian, K L Davi. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. Journal of medicinal chemistry vol 32 issue 8 1989 2754707 Compounds 1a and 1p, which showed less acute toxicity in both rats and mice than THA, are in phase II and phase I clinical trials, respectively, for Alzheimer's disease. 1989-09-07 2022-01-07 rat
J V Halliwell, E A Grov. 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones. European journal of pharmacology vol 163 issue 2-3 1989 2721578 The cooperativity of this latter action of THA with its well-known anticholinesterase activity is discussed in relation to the therapeutic effects of THA in treating Alzheimer's disease. 1989-07-12 2022-01-07 Not clear
D A Palmieri, D A Butterfiel. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes. Progress in clinical and biological research vol 292 issue 1989 2726917 Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes. 1989-07-10 2022-01-07 Not clear
J Byrne, T Ari. Tetrahydroaminoacridine (THA) in Alzheimer's disease. BMJ (Clinical research ed.) vol 298 issue 6677 1989 2497817 Tetrahydroaminoacridine (THA) in Alzheimer's disease. 1989-06-29 2022-01-07 Not clear
S Vida, L Gauthier, S Gauthie. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood. Canadian journal of psychiatry. Revue canadienne de psychiatrie vol 34 issue 3 1989 2655861 Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood. 1989-06-23 2022-01-07 Not clear
P B Reiner, E G McGee. THA increases action potential duration of central histamine neurons in vitro. European journal of pharmacology vol 155 issue 3 1989 3148476 Long-term administration of 9-amino-1,2,3,4-tetrahydroacridine (THA) has been reported to produce marked clinical improvement in patients suffering from Alzheimer's disease. 1989-04-27 2022-01-07 Not clear
P B Reiner, E G McGee. THA increases action potential duration of central histamine neurons in vitro. European journal of pharmacology vol 155 issue 3 1989 3148476 By its effect upon action potential duration, THA may increase release of transmitter from the axon terminals of cortically projecting aminergic neurons which have been shown to degenerate in Alzheimer's disease. 1989-04-27 2022-01-07 Not clear
J de Belleroche, I M Gardine. Inhibitory effect of 1,2,3,4-tetrahydro-9-aminoacridine on the depolarization-induced release of GABA from cerebral cortex. British journal of pharmacology vol 94 issue 4 1989 3207970 1,2,3,4-Tetrahydro-9-aminoacridine (THA) has an inhibitory effect on the activity of acetylcholinesterase which has led to its use in the treatment of Alzheimer's disease. 1989-02-21 2022-01-07 Not clear
E K Perry, C J Smith, J A Court, J R Bonham, M Rodway, J R Atac. Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neuroscience letters vol 91 issue 2 1988 3185960 Tetrahydroaminoacridine (THA) has recently been reported to be more useful in the treatment of Alzheimer's disease than physostigmine. 1988-12-22 2022-01-07 Not clear
G E Gibson, T Mange. Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine. Biochemical pharmacology vol 37 issue 21 1988 2847755 Both 4-AP and THA have been used to treat Alzheimer's disease. 1988-12-15 2022-01-07 Not clear
B D Pearce, L T Potte. Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptors. Neuroscience letters vol 88 issue 3 1988 3386874 Tetrahydroaminoacridine (THA) has been reported to improve the memory of persons with Alzheimer's disease, but its mechanism of action is uncertain. 1988-07-29 2022-01-07 Not clear
L Hayward, H Brodat. THA and Alzheimer's disease. The Australian and New Zealand journal of psychiatry vol 21 issue 4 1988 3449055 THA and Alzheimer's disease. 1988-06-03 2022-01-07 Not clear
B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences vol 42 issue 9 1988 2893967 Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. 1988-03-29 2022-01-07 Not clear
B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences vol 42 issue 9 1988 2893967 In a recent study we have documented the acetylcholinesterase and outward K+-current inhibiting activity of 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug reportedly active in the treatment of Alzheimer patients. 1988-03-29 2022-01-07 Not clear
B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences vol 42 issue 9 1988 2893967 It is concluded from these experiments that the effects of THA on monoaminergic neurotransmission might contribute to the alleged therapeutic action of THA in Alzheimer's disease. 1988-03-29 2022-01-07 Not clear
M M Mesulam, C Geula, M A Mor\\xc3\\xa1. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Annals of neurology vol 22 issue 6 1988 3435078 The histochemical distribution of cholinesterases in the cerebral cortex and their response to cholinesterase inhibitors such as physostigmine and tetrahydroaminoacridine (THA) were investigated in brains from patients with Alzheimer's disease and control subjects. 1988-02-26 2022-01-07 human
L Nilsson, A Adem, J Hardy, B Winblad, A Nordber. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? Journal of neural transmission vol 70 issue 3-4 1988 3681290 Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? 1988-01-20 2022-01-07 Not clear
L J Fitten, J F Flood, C F Baxter, K H Tachiki, K Perryma. Long-term oral administration of memory-enhancing doses of tacrine in mice: a study of potential toxicity and side effects. Journal of gerontology vol 42 issue 6 1987 3680887 Recently, tacrine (1, 2, 3, 4-tetrahydro-9-aminoacridine; THA; TAC) has received international attention as an oral agent capable of relieving some of the cognitive symptoms accompanying Alzheimer's disease (AD). 1987-12-30 2022-01-07 mouse
Page: 
1